

12 Jul 2023 | **Data**

Despite Pfizer/Seagen's Splash, Deals Are Staying Small

First Half 2023 Deal-Making Infographic

by **Joseph Haas**

Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.

Biopharmaceutical M&A activity started with a bang in 2023, as [Pfizer Inc.](#)'s 13 March acquisition of [Seagen Inc.](#) for \$43bn was the sector's largest buyout since a pair of mega-mergers ([Bristol Myers Squibb Company/Celgene Corporation](#) and [AbbVie Inc./Allergan plc](#)) in 2019. That deal, combined with [Merck & Co., Inc.](#)'s \$10.8bn deal for [Prometheus Biosciences, Inc](#) on 16 April and on the heels of [Amgen, Inc.](#)'s \$27.8bn acquisition of [Horizon Therapeutics plc](#) announced in December 2022, raised hopes that the industry might see more major transactions. But a look at deal statistics for the first half shows that big pharma by and large remains committed to smaller acquisitions.

The cluster of mega-deals drove up aggregate spending on biopharma M&A, which more than doubled the total spend in the first half of 2023 compared to the first two quarters of 2022. Average M&A size also doubled from the previous year as well, but the increase was largely driven by Pfizer's Seagen acquisition – excluding that, average M&A value falls from \$2.26bn to \$881m, a decline from first half 2022.

Overall, a continued emphasis on smaller, bolt-on deals remains in place from previous years as companies look to build on their existing strengths in therapeutic areas and/or treatment modalities, while avoiding larger deals that are harder to

Biopharma M&A's Busy Pace Expected To Continue During 2023's Second Half

integrate.

Looking at alliance deal-making in the first half of 2023 provides a clearer picture of the continuing trend, as biopharma companies are looking to add, but in a measured way that reflects the constrained financial market at present. Total deals declined by more than 25%, but aggregate potential value is nearly level with that recorded in the first half of 2022, as is the number of alliances with potential of \$1bn or more. Average deal value is up compared to 2022, but that is a challenging metric to assess as a significant portion of the earnouts in alliance deals are unlikely to be realized. (Also see "[The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?](#)" - Scrip, 24 Aug, 2022.)

So far, M&A and alliance deal-making in 2023 looks somewhat like a reprise of 2022's activity during the first six months. Where full year 2022 was buoyed by the Amgen/Horizon merger at the end of the year, the Pfizer/Seagen deal early this year is likely to be a similar outlier increasing the averages for 2023. (Also see "[2022 Deal-Making Snapshot: One Big Deal Didn't Change The Downward Trends](#)" - Scrip, 21 Apr, 2023.) The next six months will test how biopharma prevails in the challenging economic climate.

By Joseph Haas

12 Jul 2023

Analysts from PwC see multiple factors that should continue to drive bolt-on deals valued at \$1bn or more, but heightened FTC scrutiny of large M&A may discourage bigger transactions.

[Read the full article here](#)

First Half 2023 Deals Review

[M&A Overview](#)

[Alliances Overview](#)

[Click here to explore this interactive content online](#) 

[Click here to explore this interactive content online](#) 



Source: Biomedtracker and *Scrip*

Design: Nancy Pham